ImmuPharma (LON:IMM) Shares Up 20.4% – Here’s Why

Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 20.4% on Friday. The company traded as high as GBX 2.90 and last traded at GBX 2.90. Approximately 4,199,980 shares changed hands during trading, an increase of 67% from the average daily volume of 2,518,765 shares. The stock had previously closed at GBX 2.40.

ImmuPharma Stock Up 20.4%

The stock has a market cap of £18.10 million, a price-to-earnings ratio of -3.49 and a beta of 3.02. The business has a 50-day moving average of GBX 3.46 and a 200-day moving average of GBX 4.48.

ImmuPharma (LON:IMM – Get Free Report) last released its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. Equities analysts anticipate that ImmuPharma plc will post -339.00 earnings per share for the current year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Read More

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.